沃替西汀薄膜包衣片BRINTELLIX(vortioxetine film coated tablet)为治疗成年人重度抑郁症(MDD)的新药 商品名：Brintellix 通用名：Vortioxetine 别名:Lu AA21004 中文名：沃替西汀 药物分类：选择性血清素再摄取抑制剂(选择性5-羟色胺再摄取抑制剂,SSRIs) 批准时间：2013年9月30日 （美国）, 2013年12月27日 （欧盟） 作用机理：5-HT3和5-HT7受体拮抗剂、5-HT1B受体部分激动剂、5-HT1A受体激动剂、5-羟色胺转运蛋白（SERT）抑制剂. 适应证和用途 BRINTELLIX是适用为重度抑郁症(MDD)的治疗。 剂量和给药方法 （1）推荐开始剂量是10mg口服给予每天1次不受食物影响 （2）当耐受剂量应增加至20mg/day。 （3）对不能耐受较高剂量患者考虑5mg/day。 （4）BRINTELLIX可突然停药。 但是，建议如可能完全终止前1周15 mg/day或20mg/day剂量减低至10 mg/day。 （5）在已知CYP2D6代谢差患者中最大推荐剂量为10mg/day。 剂型和规格 薄膜包衣片5mg，10mg，15mg,和20mg。 禁忌证 （1）对vortioxetine或BRINTELLIX制剂任何组分超敏性。 （2）单胺氧化酶抑制剂(MAOIs)：不要意向使用MAOIs与BRINTELLIX或停止用BRINTELLIX治疗21天内治疗精神疾病。在一种MAOI停止14天内不要意向使用BRINTELLIX治疗精神疾病。此外，正在用利奈唑胺[linezolid]或静脉亚甲蓝[methylene blue]治疗患者不要开始BRINTELLIX (4)。 （1）用5-HT能抗抑郁药(SSRIs，SNRIs，和其他)，包括用BRINTELLIX，两者当单独用，但尤其是当与其他5-HT能药物共同给药时曾报道5-HT综合证(包括曲坦类药物[triptans]，三环类抗抑郁药[tricyclic antidepressants]，芬太尼[fentanyl]，锂[lithium]，曲马多[tramadol]，色氨酸，丁螺环酮[buspirone]，和圣约翰草[St. John's Wort])。如果出现这种症状，终止BRINTELLIX和开始支持治疗。如果临床上想要BRINTELLIX与其他5-HT药物的同时使用，患者应注意对5-HT综合证潜在风险增加，尤其是治疗开始和剂量增加期间。 （2）用5-HT能抗抑郁药治疗(SSRIs，SNRIs，和其他)可能增加异常出血的风险。当BRINTELLIX与非甾体抗炎药(NSAIDs)，阿司匹林[aspirin]，或影响凝血其他药物共同给药时患者应谨慎注意关于出血风险增加。 （3）抗抑郁药治疗可出现躁狂/轻躁狂的激活。筛选躁郁症患者。 （4）与抗利尿激素不适当分泌综合证(SIADH)可能伴发低钠血症 不良反应 最常见不良反应(发生率 ≥5%和至少安慰剂率的2倍)是：恶心，便秘和呕吐(6)。 报告怀疑不良反应，联系Takeda Pharmaceuticals电话1-877-TAKEDA-7(1-877-825-3327)或FDA电话1¬800-FDA-1088或www.fda.gov/medwatch. 药物相互作用 （1）CYP2D6的强抑制剂：当强CYP2D6抑制剂(如，安非他酮[bupropion]，氟西汀[fluoxetine]，帕罗西汀[paroxetine]，或奎尼丁[quinidine])被共同给药减低BRINTELLIX剂量一半(2.6和7.3)。 （2）强CYP诱导剂：当一种强CYP诱导剂(如，利福平[rifampin]，卡马西平[carbamazepine]，或苯妥英钠[phenytoin])被共同给药共14天以上考虑增加BRINTELLIX剂量。最大推荐剂量不应超过原剂量3倍。 特殊人群中使用 （1）妊娠：根据动物资料，BRINTELLIX可能致胎儿危害。 （2）哺乳母亲：终止BRINTELLIX或终止哺乳. Brintellix tablets 5, 10 and 20mg 1. Name of the medicinal product Brintellix 5 mg film-coated tablets Brintellix 10 mg film-coated tablets Brintellix 20 mg film-coated tablets 2. Qualitative and quantitative composition Brintellix 5 mg tablet: Each film-coated tablet contains vortioxetine hydrobromide equivalent to 5 mg vortioxetine Brintellix 10 mg tablet: Each film-coated tablet contains vortioxetine hydrobromide equivalent to 10 mg vortioxetine Brintellix 20 mg tablet: Each film-coated tablet contains vortioxetine hydrobromide equivalent to 20 mg vortioxetine For the full list of excipients, see section 6.1. 3. Pharmaceutical form Film-coated tablet. Pink, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with “TL” on one side and “5” on the other side. Yellow, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with “TL” on one side and “10” on the other side. Red, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with “TL” on one side and “20” on the other side. 4. Clinical particulars 4.1 Therapeutic indications Brintellix is indicated for the treatment of major depressive episodes in adults. 4.2 Posology and method of administration Posology The starting and recommended dose of Brintellix is 10 mg vortioxetine once daily in adults less than 65 years of age. Depending on individual patient response, the dose may be increased to a maximum of 20 mg vortioxetine once daily or decreased to a minimum of 5 mg vortioxetine once daily. After the depressive symptoms resolve, treatment for at least 6 months is recommended for consolidation of the antidepressive response. Treatment discontinuation Patients treated with Brintellix can abruptly stop taking the medicinal product without the need for a gradual reduction in dose (see section 5.1). Special populations Elderly patients The lowest effective dose of 5 mg vortioxetine once daily should always be used as the starting dose in patients ≥ 65 years of age. Caution is advised when treating patients ≥ 65 years of age with doses higher than 10 mg vortioxetine once daily for which data are limited (see section 4.4). Cytochrome P450 inhibitors Depending on individual patient response, a lower dose of vortioxetine may be considered if a strong CYP2D6 inhibitor (e.g. bupropion, quinidine, fluoxetine, paroxetine) is added to Brintellix treatment (see section 4.5). Cytochrome P450 inducers Depending on individual patient response, a dose adjustment of vortioxetine may be considered if a broad cytochrome P450 inducer (e.g. rifampicin, carbamazepine, phenytoin) is added to Brintellix treatment (see section 4.5). Paediatric population The safety and efficacy of Brintellix in children and adolescents aged less than 18 years have not been established. No data are available (see section 4.4). Method of administration Brintellix is for oral use. The film-coated tablets can be taken with or without food. 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Concomitant use with nonselective monoamine oxidase inhibitors (MAOIs) or selective MAO-A inhibitors (see section 4.5). 4.4 Special warnings and precautions for use Use in paediatric population Brintellix is not recommended for the treatment of depression in patients aged less than 18 years since the safety and efficacy of vortioxetine have not been established in this age group (see section 4.2). In clinical studies in children and adolescents treated with other antidepressants, suicide-related behaviour (suicide attempt and suicidal thoughts) and hostility (predominantly aggression, oppositional behaviour, anger) were more frequently observed than in those treated with placebo. Suicide/suicidal thoughts or clinical worsening Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery. Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical studies of antidepressants in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo, in patients less than 25 years old. Close supervision of patients and in particular those at high risk should accompany treatment especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted to the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present. Seizures Seizures are a potential risk with antidepressants. Therefore, Brintellix should be introduced cautiously in patients who have a history of seizures or in patients with unstable epilepsy (see section 4.5). Treatment should be discontinued in any patient who develops seizures or for whom there is an increase in seizure frequency. Serotonin Syndrome (SS) or Neuroleptic Malignant Syndrome (NMS) Serotonin Syndrome (SS) or Neuroleptic Malignant Syndrome (NMS), potentially life-threatening conditions, may occur with Brintellix. The risk of SS or NMS is increased with concomitant use of serotonergic-active substances (including triptans), medicinal products that impair the metabolism of serotonin (including MAOIs), antipsychotics, and other dopamine antagonists. Patients should be monitored for the emergence of signs and symptoms of SS or NMS (see sections 4.3 and 4.5). Serotonin Syndrome symptoms include mental status changes (e.g. agitation, hallucinations, coma), autonomic instability (e.g. tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, uncoordination) and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea). If this occurs, treatment with Brintellix should be discontinued immediately and symptomatic treatment should be initiated. Mania/hypomania Brintellix should be used with caution in patients with a history of mania/hypomania and should be discontinued in any patient entering a manic phase. Haemorrhage Bleeding abnormalities, such as ecchymoses, purpura and other haemorrhagic events, such as gastrointestinal or gynaecological bleeding, have been reported rarely with the use of antidepressants with serotonergic effect (SSRIs, SNRIs). Caution is advised in patients taking anticoagulants and/or medicinal products known to affect platelet function [e.g. atypical antipsychotics and phenothiazines, most tricyclic antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid (ASA)] (see section 4.5) and in patients with known bleeding tendencies/disorders. Hyponatraemia Hyponatraemia, probably due to inappropriate antidiuretic hormone secretion (SIADH), has been reported rarely with the use of antidepressants with serotonergic effect (SSRIs, SNRIs). Caution should be exercised in patients at risk, such as the elderly, patients with cirrhosis of the liver or patients concomitantly treated with medications known to cause hyponatraemia. Discontinuation of Brintellix should be considered in patients with symptomatic hyponatraemia and appropriate medical intervention should be instituted. Elderly Data on the use of Brintellix in elderly patients with major depressive episodes are limited. Therefore, caution should be exercised when treating patients ≥ 65 years of age with doses higher than 10 mg vortioxetine once daily (see sections 4.8 and 5.2). Renal impairment Limited data are available for patients with severe renal impairment. Caution should therefore be exercised (see section 5.2). Hepatic impairment Vortioxetine has not been studied in patients with severe hepatic impairment and caution should be exercised when treating these patients (see section 5.2). 4.5 Interaction with other medicinal products and other forms of interaction Vortioxetine is extensively metabolised in the liver, primarily through oxidation catalysed by CYP2D6 and to a minor extent CYP3A4/5 and CYP2C9 (see section 5.2). Potential for other medicinal products to affect vortioxetine Irreversible non-selective MAOIs Due to the risk of Serotonin Syndrome, vortioxetine is contraindicated in any combination with irreversible non-selective MAOIs. Vortioxetine must not be initiated for at least 14 days after discontinuation of treatment with an irreversible non-selective MAOI. Vortioxetine must be discontinued for at least 14 days before starting treatment with an irreversible non-selective MAOI (see section 4.3). Reversible, selective MAO-A inhibitor (moclobemide) The combination of vortioxetine with a reversible and selective MAO-A inhibitor, such as moclobemide, is contraindicated (see section 4.3). If the combination proves necessary, the added medicinal product should be given with minimum dosage and under close clinical monitoring for Serotonin Syndrome (see section 4.4). Reversible, non-selective MAOI (linezolid) The combination of vortioxetine with a weak reversible and non-selective MAOI, such as the antibiotic linezolid, is contraindicated (see section 4.3). If the combination proves necessary, the added medicinal product should be given with minimum dosage and under close clinical monitoring for Serotonin Syndrome (see section 4.4). Irreversible, selective MAO-B inhibitor (selegiline, rasagiline) Although a lower risk of Serotonin Syndrome is expected with selective MAO-B inhibitors than with MAO-A inhibitors, the combination of vortioxetine with irreversible MAO-B inhibitors, such as selegiline or rasagiline should be administered with caution. Close monitoring for Serotonin Syndrome is necessary if used concomitantly (see section 4.4). Serotonergic medicinal products Co-administration of medicinal products with serotonergic effect (e.g. tramadol, sumatriptan and other triptans) may lead to Serotonin Syndrome (see section 4.4). St. John's wort Concomitant use of antidepressants with serotonergic effect and herbal remedies containing St. John's wort (Hypericum perforatum) may result in a higher incidence of adverse reactions including Serotonin Syndrome (see section 4.4). Medicinal products lowering the seizure threshold Antidepressants with serotonergic effect can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold [e.g. antidepressants (tricyclics, SSRIs, SNRIs), neuroleptics (phenothiazines, thioxanthenes and butyrophenones), mefloquine, bupropion, tramadol] (see section 4.4). ECT (electroconvulsive therapy) There is no clinical experience with concurrent administration of vortioxetine and ECT, therefore caution is advisable. CYP2D6 inhibitors The exposure to vortioxetine increased 2.3-fold for area under the curve (AUC) when vortioxetine 10 mg/day was co-administered with bupropion (a strong CYP2D6 inhibitor 150 mg twice daily) for 14 days in healthy subjects. Co-administration resulted in a higher incidence of adverse reactions when bupropion was added to vortioxetine than when vortioxetine was added to bupropion. Depending on individual patient response, a lower dose of vortioxetine may be considered if a strong CYP2D6 inhibitor (e.g. bupropion, quinidine, fluoxetine, paroxetine) is added to vortioxetine treatment (see section 4.2). CYP3A4 inhibitors and CYP2C9 inhibitors When vortioxetine was co-administered following 6 days of ketoconazole 400 mg/day (a CYP3A4/5 and P-glycoprotein inhibitor) or following 6 days of fluconazole 200 mg/day (a CYP2C9, CYP2C19, and CYP3A4/5 inhibitor) in healthy subjects, a 1.3-fold and 1.5-fold increase, respectively, in vortioxetine AUC was observed. No dose adjustment is needed. Interactions in CYP2D6 poor metabolisers Co-administration of strong inhibitors of CYP3A4 (such as itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, conivaptan and many of the HIV protease inhibitors) and inhibitors of CYP2C9 (such as fluconazole and amiodarone) to CYP2D6 poor metabolisers (see section 5.2) has not been investigated specifically, but it is anticipated that it will lead to a more marked increased exposure of vortioxetine in these patients as compared to the moderate effect described above. No inhibitory effect of 40 mg single-dose omeprazole (CYP2C19 inhibitor) was observed on the multiple-dose pharmacokinetics of vortioxetine in healthy subjects. Cytochrome P450 inducers When a single dose of 20 mg vortioxetine was co-administered following 10 days of rifampicin 600 mg/day (a broad inducer of CYP isozymes) in healthy subjects, a 72% decrease in AUC of vortioxetine was observed. Depending on individual patient response, a dose adjustment may be considered if a broad cytochrome P450 inducer (e.g. rifampicin, carbamazepine, phenytoin) is added to vortioxetine treatment (see section 4.2). Alcohol No effect on the pharmacokinetics of vortioxetine or ethanol and no significant impairment, relative to placebo, in cognitive function were observed when vortioxetine in a single dose of 20 mg or 40 mg was co-administered with a single dose of ethanol (0.6 g/kg) in healthy subjects. However, alcohol intake is not advisable during antidepressant treatment. Acetylsalicylic acid No effect of multiple doses of acetylsalicylic acid 150 mg/day on the multiple-dose pharmacokinetics of vortioxetine was observed in healthy subjects. Potential for vortioxetine to affect other medicinal products Anticoagulants and antiplatelet medicinal products No significant effects, relative to placebo, were observed in INR, prothrombin or plasma R-/S-warfarin values following co-administration of multiple doses of vortioxetine with stable doses of warfarin in healthy subjects. Also, no significant inhibitory effect, relative to placebo, on platelet aggregation or pharmacokinetics of acetylsalicylic acid or salicylic acid was observed when acetylsalicylic acid 150 mg/day was co-administered following multiple doses of vortioxetine administration in healthy subjects. However, as for other serotonergic medicinal products, caution should be exercised when vortioxetine is combined with oral anticoagulants or antiplatelet medicinal products due to a potential increased risk of bleeding attributable to a pharmacodynamic interaction (see section 4.4). Cytochrome P450 substrates In vitro, vortioxetine did not show any relevant potential for inhibition or induction of cytochrome P450 isozymes (see section 5.2). Following multiple doses of vortioxetine, no inhibitory effect was observed in healthy subjects for the cytochrome P450 isozymes CYP2C19 (omeprazole, diazepam), CYP3A4/5 (ethinyl estradiol, midazolam), CYP2B6 (bupropion), CYP2C9 (tolbutamide, S-warfarin), CYP1A2 (caffeine) or CYP2D6 (dextromethorphan). No pharmacodynamic interactions were observed. No significant impairment, relative to placebo, in cognitive function was observed for vortioxetine following co-administration with a single 10 mg dose of diazepam. No significant effects, relative to placebo, were observed in the levels of sex hormones following co-administration of vortioxetine with a combined oral contraceptive (ethinyl estradiol 30 µg/ levonorgestrel 150 µg). Lithium, tryptophan No clinically relevant effect was observed during steady-state lithium exposure following co-administration with multiple doses of vortioxetine in healthy subjects. However, there have been reports of enhanced effects when antidepressants with serotonergic effect have been given together with lithium or tryptophan; therefore, concomitant use of vortioxetine with these medicinal products should be undertaken with caution. 4.6 Fertility, pregnancy and lactation Pregnancy There are limited data from the use of vortioxetine in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The following symptoms may occur in the newborn after maternal use of a serotonergic medicinal product in the later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty sleeping. These symptoms could be due to either discontinuation effects or excess serotonergic activity. In the majority of instances, such complications began immediately or soon (< 24 hours) after delivery. Epidemiological data suggest that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). Although no studies have investigated the association of PPHN with vortioxetine treatment, this potential risk cannot be ruled out taking into account the related mechanism of action (increase in serotonin concentrations). Brintellix should not be used during pregnancy unless the clinical condition of the woman requires treatment with vortioxetine. Breast-feeding Available data in animals have shown excretion of vortioxetine/ vortioxetine metabolites in milk. It is expected that vortioxetine will be excreted into human milk (see section 5.3). A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Brintellix treatment taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. Fertility Fertility studies in male and female rats showed no effect of vortioxetine on fertility, sperm quality or mating performance (see section 5.3). Human case reports with medicinal products from the related pharmacological class of antidepressants (SSRIs) have shown an effect on sperm quality that is reversible. Impact on human fertility has not been observed so far. 4.7 Effects on ability to drive and use machines Brintellix has no or negligible influence on the ability to drive and use machines. However, patients should exercise caution when driving or operating hazardous machinery, especially when starting treatment with vortioxetine or when changing the dose. 4.8 Undesirable effects Summary of the safety profile The most common adverse reaction was nausea. Adverse reactions were usually mild or moderate and occurred within the first two weeks of treatment. The reactions were usually transient and did not generally lead to cessation of therapy. Gastrointestinal adverse reactions, such as nausea, occurred more frequently in women than men. Tabulated list of adverse reactions Adverse reactions are listed below using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). SYSTEM ORGAN CLASS FREQUENCY ADVERSE REACTION Psychiatric disorders Common Abnormal dreams Nervous system disorders Common Dizziness Unknown Serotonin Syndrome Vascular disorders Uncommon Flushing Gastrointestinal disorders Very common Nausea Common Diarrhoea, Constipation, Vomiting Skin and subcutaneous tissue disorders Common Pruritus, including pruritus generalised Uncommon Night sweats Description of selected adverse reactions Elderly patients For doses ≥10 mg vortioxetine once daily, the withdrawal rate from the studies was higher in patients aged ≥65 years. For doses of 20 mg vortioxetine once daily, the incidences of nausea and constipation were higher in patients aged ≥65 years (42% and 15%, respectively) than in patients aged <65 years (27% and 4%, respectively)(see section 4.4). Sexual dysfunction In clinical studies, sexual dysfunction was assessed using the Arizona Sexual Experience Scale (ASEX). Doses of 5 to 15 mg showed no difference to placebo. However, the 20 mg dose of vortioxetine was associated with an increase in treatment-emergent sexual dysfunction (TESD)(see section 5.1) . Class effect Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving a drug from related pharmacological classes of antidepressants (SSRIs or TCAs). The mechanism behind this risk is unknown, and it is not known if this risk is also relevant for vortioxetine Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard 4.9 Overdose There is limited experience with vortioxetine overdose. Ingestion of vortioxetine in the dose range of 40 to 75 mg has caused an aggravation of the following adverse reactions: nausea, postural dizziness, diarrhoea, abdominal discomfort, generalised pruritus, somnolence and flushing. Management of overdose should consist of treating clinical symptoms and relevant monitoring. Medical follow-up in a specialised environment is recommended. 5. Pharmacological properties 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Psychoanaleptics; Other antidepressants, ATC-code: N06AX26 Mechanism of action The mechanism of action of vortioxetine is thought to be related to its direct modulation of serotonergic receptor activity and inhibition of the serotonin (5-HT) transporter. Nonclinical data indicate that vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of the 5-HT transporter, leading to modulation of neurotransmission in several systems, including predominantly the serotonin but probably also the norepinephrine, dopamine, histamine, acetylcholine, GABA and glutamate systems. This multimodal activity is considered responsible for the antidepressant and anxiolytic-like effects and the improvement of cognitive function, learning and memory observed with vortioxetine in animal studies. However, the precise contribution of the individual targets to the observed pharmacodynamic profile remains unclear and caution should be applied when extrapolating animal data directly to man. In humans, two positron emission tomography (PET) studies have been conducted using 5-HT transporter ligands (11C-MADAM or 11C-DASB) to quantify the 5-HT transporter occupancy in the brain across different dose levels. The mean 5-HT transporter occupancy in the raphe nuclei was approximately 50% at 5 mg/day, 65% at 10 mg/day and increased to above 80% at 20 mg/day. Clinical efficacy and safety The efficacy and safety of vortioxetine have been studied in a clinical programme that included more than 6,700 patients, of whom more than 3,700 were treated with vortioxetine in short-term (≤12 weeks) studies of major depressive disorder (MDD). Twelve double-blind, placebo controlled, 6/8-week, fixed-dose studies have been conducted to investigate the short-term efficacy of vortioxetine in MDD in adults (including the elderly). The efficacy of vortioxetine was demonstrated with at least one dosage group across 9 of the 12 studies, showing at least a 2-point difference to placebo in the Montgomery and Åsberg Depression Rating Scale (MADRS) or Hamilton Depression Rating Scale 24-item (HAM-D24) total score. This was supported by clinical relevance as demonstrated by the proportions of responders and remitters and the improvement in the Clinical Global Impression – Global Improvement (CGI-I) score. The efficacy of vortioxetine increased with increasing dose. The effect in the individual studies was supported by the meta-analysis (MMRM) of the mean change from baseline in MADRS total score at Week 6/8 in the short-term, placebo-controlled studies in adults. In the meta-analysis, the overall mean difference to placebo across the studies was statistically significant: -2.3 points (p = 0.007), -3.6 points (p <0.001), and -4.6 points (p <0.001) for the 5, 10, and 20 mg/day doses, respectively; the 15 mg/day dose did not separate from placebo in the meta-analysis, but the mean difference to placebo was -2.6 points. The efficacy of vortioxetine is supported by the pooled responder analysis, in which the proportion of responders ranged from 46% to 49% for vortioxetine versus 34% for placebo (p <0.01; NRI analysis). Furthermore, vortioxetine, in the dose range of 5-20 mg/day, demonstrated efficacy on the broad range of depressive symptoms (assessed by improvement in all MADRS single–item scores). The efficacy of vortioxetine 10 or 20 mg/day was further demonstrated in a 12-week, double-blind, flexible-dose comparative study versus agomelatine 25 or 50 mg/day in patients with MDD. Vortioxetine was statistically significantly better than agomelatine as measured by improvement in the MADRS total score and supported by the clinical relevance as demonstrated by the proportions of responders and remitters and improvement in the CGI-I. Maintenance The maintenance of antidepressant efficacy was demonstrated in a relapse-prevention study. Patients in remission after an initial 12-week open-label treatment period with vortioxetine were randomised to vortioxetine 5 or 10 mg/day or placebo and observed for relapse during a double-blind period of at least 24 weeks (24 to 64 weeks). Vortioxetine was superior (p=0.004) to placebo on the primary outcome measure, the time to relapse of MDD, with a hazard ratio of 2.0; that is, the risk of relapse was two times higher in the placebo group than in the vortioxetine group. Elderly In the 8-week, double-blind, placebo-controlled, fixed-dose study in elderly depressed patients (aged ≥65 years, n=452, 156 of whom were on vortioxetine), vortioxetine 5 mg/day was superior to placebo as measured by improvement in the MADRS and HAM-D24 total scores. The effect seen with vortioxetine was a 4.7 point difference to placebo in MADRS total score at Week 8 (MMRM analysis). Patients with severe depression or with depression and high levels of anxiety symptoms In severely depressed patients (baseline MADRS total score ≥30) and in depressed patients with a high level of anxiety symptoms (baseline HAM-A total score ≥20) vortioxetine also demonstrated efficacy in the short-term studies in adults (the overall mean difference to placebo in MADRS total score at Week 6/8 ranged from 2.8 to 7.3 points and from 3.6 to 7.3 points, respectively,(MMRM analysis)). In the dedicated study in elderly, vortioxetine was also effective in these patients. The maintenance of antidepressant efficacy was also demonstrated in this patient population in the long-term relapse prevention study. Effects of vortioxetine on the Digit Symbol Substitution Test (DSST), the University of California San Diego Performance-Based Skills Assessment (UPSA) (objective measures) and Perceived Deficits Questionnaire (PDQ) and Cognitive and Physical Functioning Questionnaire CPFQ (subjective measures) scores The efficacy of vortioxetine (5-20 mg/day) in patients with MDD has been investigated in 2 adult and 1 elderly short-term, placebo-controlled studies. Vortioxetine had a statistically significant effect versus placebo on the Digit Symbol Substitution Test (DSST), ranging from Δ = 1.75 (p = 0.019) to 4.26 (p <0.0001) in the 2 studies in adults and Δ = 2.79 (p = 0.023) in the study in the elderly. In the meta-analyses (ANCOVA, LOCF) of the mean change from baseline in DSST number of correct symbols in all 3 studies, vortioxetine separated from placebo (p<0.05) with a standardised effect size of 0.35. When adjusting for the change in MADRS the total score in the meta-analysis of the same studies showed that vortioxetine separated from placebo (p<0.05) with a standardised effect size of 0.24. One study assessed the effect of vortioxetine on functional capacity using the University of California San Diego Performance-Based Skills Assessment (UPSA). Vortioxetine separated from placebo statistically with results of 8.0 for vortioxetine versus 5.1 points for placebo (p=0.0003). In one study, vortioxetine was superior to placebo on subjective measures, evaluated using the Perceived Deficits Questionnaire with results of -14.6 for vortioxetine and -10.5 for placebo (p=0.002). Vortioxetine did not separate from placebo on subjective measures when evaluated using the Cognitive and Physical Functioning Questionnaire with results of -8.1 for vortioxetine versus -6.9 for placebo (p=0.086). Tolerability and safety The safety and tolerability of vortioxetine have been established in short- and long-term studies across the dose range of 5 to 20 mg/day. For information on undesirable effects, see section 4.8. Vortioxetine did not increase the incidence of insomnia or somnolence relative to placebo. In clinical short- and long-term placebo-controlled studies, potential discontinuation symptoms were systematically evaluated after abrupt treatment cessation of vortioxetine. There was no clinically relevant difference to placebo in the incidence or nature of the discontinuation symptoms after either short-term (6-12 weeks) or long-term (24-64 weeks) treatment with vortioxetine. The incidence of self-reported adverse sexual reactions was low and similar to placebo in clinical short- and long-term studies with vortioxetine. In studies using the Arizona Sexual Experience Scale (ASEX), the incidence of treatment-emergent sexual dysfunction (TESD) and the ASEX total score showed no clinically relevant difference to placebo in symptoms of sexual dysfunction at the 5 to 15 mg/day doses of vortioxetine. For the 20 mg/day dose, an increase in TESD was seen compared to placebo (an incidence difference of 14.2%, 95% CI [1.4, 27.0]). Vortioxetine had no effect relative to placebo on body weight, heart rate, or blood pressure in clinical short- and long-term studies. No clinically significant changes were observed in hepatic or renal assessments in clinical studies. Vortioxetine has not shown any clinically significant effect on ECG parameters, including the QT, QTc, PR and QRS intervals, in patients with MDD. In a thorough QTc study in healthy subjects at doses up to 40 mg daily, no potential for the prolongation of the QTc interval was observed. Paediatric population The European Medicines Agency has waived the obligation to submit the results of studies in major depressive disorder with vortioxetine in children aged less than 7 years (see section 4.2 for information on paediatric use). The European Medicines Agency has deferred the obligation to submit the results of studies in major depressive disorder with vortioxetine in children and adolescents aged 7 to 18 years (see section 4.2 for information on paediatric use). 5.2 Pharmacokinetic properties Absorption Vortioxetine is slowly, but well absorbed after oral administration and the peak plasma concentration is reached within 7 to 11 hours. Following multiple dosing of 5, 10, or 20 mg/day, mean Cmax values of 9 to 33 ng/mL were observed. The absolute bioavailability is 75%. No effect of food on the pharmacokinetics was observed (see section 4.2). Distribution The mean volume of distribution (Vss) is 2,600 L, indicating extensive extravascular distribution. Vortioxetine is highly bound to plasma proteins (98 to 99%) and the binding appears to be independent of vortioxetine plasma concentrations. Biotransformation Vortioxetine is extensively metabolised in the liver, primarily through oxidation catalysed by CYP2D6 and to a minor extent CYP3A4/5 and CYP2C9, and subsequent glucuronic acid conjugation. No inhibitory or inducing effect of vortioxetine was observed in the drug-drug interaction studies for the CYP isozymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/5 (see section 4.5). Vortioxetine is a poor P-gp substrate and inhibitor. The major metabolite of vortioxetine is pharmacologically inactive. Elimination The mean elimination half-life and oral clearance are 66 hours and 33 L/h, respectively. Approximately 2/3 of the inactive vortioxetine metabolites are excreted in the urine and approximately 1/3 in the faeces. Only negligible amounts of vortioxetine are excreted in the faeces. Steady-state plasma concentrations are achieved in approximately 2 weeks. Linearity/non-linearity The pharmacokinetics are linear and time independent in the dose range studied (2.5 to 60 mg/day). In accordance with the half-life, the accumulation index is 5 to 6 based on AUC0-24h following multiple doses of 5 to 20 mg/day. Special populations Elderly In elderly healthy subjects (aged ≥65 years; n=20), the exposure to vortioxetine increased up to 27% (Cmax and AUC) compared to young healthy control subjects (aged ≤45 years) after multiple doses of 10 mg/day. The lowest effective dose of 5 mg vortioxetine once daily should always be used as the starting dose in patients ≥ 65 years (see section 4.2). However, caution should be exercised when prescribing to elderly patients at doses higher than 10 mg vortioxetine once daily (see section 4.4). Renal impairment Following a single dose of 10 mg vortioxetine, renal impairment estimated using the Cockcroft-Gault formula (mild, moderate, or severe; n=8 per group) caused modest exposure increases (up to 30%), compared to healthy matched controls. In patients with end-stage renal disease, only a small fraction of vortioxetine was lost during dialysis (AUC and Cmax were 13% and 27% lower, respectively; n=8) following a single 10 mg dose of vortioxetine. No dose adjustment is needed (see section 4.4). Hepatic impairment Following a single dose of 10 mg vortioxetine, no impact of mild or moderate hepatic impairment (Child-Pugh Criteria A or B; n=8 per group) was observed on the pharmacokinetics of vortioxetine (changes in AUC were less than 10%). No dose adjustment is needed (see section 4.2). Vortioxetine has not been studied in patients with severe hepatic impairment and caution should be exercised when treating these patients (see section 4.4). CYP2D6 gene types The plasma concentration of vortioxetine was approximately two times higher in CYP2D6 poor metabolisers than in extensive metabolisers. Co-administration of strong CYP3A4/2C9 inhibitors to CYP2D6 poor metabolisers could potentially result in higher exposure (see section 4.5). In CYP2D6 ultra-rapid metabolisers, the plasma concentration of vortioxetine 10 mg/day were between those obtained in extensive metabolisers at 5 mg/day and 10 mg/day. As for all patients, depending on individual patient response, a dose adjustment may be considered (see section 4.2). 5.3 Preclinical safety data Administration of vortioxetine in the general toxicity studies in mice, rats and dogs was mainly associated with CNS-related clinical signs. These included salivation (rat and dog), pupil dilatation (dog), and two incidences of convulsions in dogs in the general toxicity study programme. A no-effect level for convulsions was established with a corresponding safety margin of 5 considering the maximum recommended therapeutic dose of 20 mg/day. Target organ toxicity was restricted to kidneys (rats) and liver (mice and rats). The changes in the kidney in rats (glomerulonephritis, renal tubular obstruction, crystalline material in renal tubule) and in the liver of mice and rats (hepatocellular hypertrophy, hepatocyte necrosis, bile duct hyperplasia, crystalline material in bile ducts) were seen at exposures more than 10-fold (mice) and 2-fold (rats) the human exposure at the maximum recommended therapeutic dose of 20 mg/day. These findings were mainly attributed to rodent-specific vortioxetine-related crystalline material obstruction of the renal tubules and the bile ducts, respectively, and considered of low risk to humans. Vortioxetine was not genotoxic in a standard battery of in vitro and in vivo tests. Based on results from conventional 2-year carcinogenicity studies in mice or rats, vortioxetine is not considered to pose a risk of carcinogenicity in humans. Vortioxetine had no effect on rat fertility, mating performance, reproductive organs, or sperm morphology and motility. Vortioxetine was not teratogenic in rats or rabbits, but reproductive toxicity in terms of effects on foetal weight and delayed ossification were seen in the rat at exposures more than 10-fold the human exposure at the maximum recommended therapeutic dose of 20 mg/day. Similar effects were seen in the rabbit at sub-therapeutic exposure. In a pre- and post-natal study in rats, vortioxetine was associated with increased pup mortality, reduced bodyweight gain, and delayed pup development at doses that did not result in maternal toxicity and with associated exposures similar to those achieved in humans following administration of vortioxetine 20 mg/day (see section 4.6). Vortioxetine-related material was distributed to the milk of lactating rats (see section 4.6). In juvenile toxicity studies in rats, all vortioxetine treatment-related findings were consistent with those noted in adult animals. The active ingredient vortioxetine hydrobromide is classified as a PBT-substance (persistent, bioaccumulative and toxic; risk to fish). However, by recommended patient usage vortioxetine is considered to pose negligible risk to the aquatic and terrestrial environment (for instruction on disposal see section 6.6). 6. Pharmaceutical particulars 6.1 List of excipients Tablet core Mannitol Microcystalline cellulose Hydroxypropylcellulose Sodium starch glycolate (type A) Magnesium stearate Tablet coating Hypromellose Macrogol 400 Titanium dioxide (E171) Iron oxide red (E172) (5 mg and 20 mg tablets only) Iron oxide yellow (E172) (10 mg tablet only) 6.2 Incompatibilities Not applicable. 6.3 Shelf life 4 years. 6.4 Special precautions for storage This medicinal product does not require any special storage conditions. 6.5 Nature and contents of container Blister: Transparent; PVC/PVdC/aluminium blister. 5 mg tablets:  Pack sizes of 14, 28 and 98 film-coated tablets. 10 mg tablets:  Pack sizes of 7, 14, 28, 56 and 98 film-coated tablets. 20 mg tablets:  Pack sizes of 14, 28, 56, and 98 film-coated tablets. Perforated unit dose blisters: PVC/PVdC/aluminium. 5 mg tablets:  Pack sizes of 56 x 1 and 98 x 1 film-coated tablets. Multipack containing 126 (9 x 14) and 490 (5 x (98x1)) film-coated tablets. 10 mg tablets:  Pack sizes of 56 x 1 and 98 x 1 film-coated tablets. Multipack containing 126 (9 x 14) and 490 (5 x (98x1)) film-coated tablets. 20 mg tablets:  The pack sizes of 56 x 1 and 98 x 1 film-coated tablets. Multipack containing: 126 (9 x 14) and 490 (5 x (98 x 1)) film-coated tablets. High-density polyethylene (HDPE) tablet container. 5 mg tablets:  Pack sizes of 100 and 200 film-coated tablets. 10 mg tablets:  Pack sizes of 100 and 200 film-coated tablets. 20 mg tablets:  Pack sizes of 100 and 200 film-coated tablets. Not all pack sizes may be marketed. 6.6 Special precautions for disposal and other handling Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 7. Marketing authorisation holder H. Lundbeck A/S Ottiliavej 9 2500 Valby Denmark 8. Marketing authorisation number(s) EU/1/13/891/001 EU/1/13/891/002 EU/1/13/891/003 EU/1/13/891/004 EU/1/13/891/005 EU/1/13/891/006 EU/1/13/891/007 EU/1/13/891/008 EU/1/13/891/009 EU/1/13/891/010 EU/1/13/891/011 EU/1/13/891/012 EU/1/13/891/013 EU/1/13/891/014 EU/1/13/891/015 EU/1/13/891/016 EU/1/13/891/017 EU/1/13/891/027 EU/1/13/891/028 EU/1/13/891/029 EU/1/13/891/030 EU/1/13/891/031 EU/1/13/891/032 EU/1/13/891/033 EU/1/13/891/034 EU/1/13/891/035 EU/1/13/891/037 EU/1/13/891/038 EU/1/13/891/039 EU/1/13/891/040 9. Date of first authorisation/renewal of the authorisation Date of first authorisation: 18 December 2013 10. Date of revision of the text 17 June 2015 Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu. 抑郁症又称抑郁障碍，以显著而持久的心境低落为主要临床特征，是心境障碍的主要类型。临床可见心境低落与其处境不相称，情绪的消沉可以从闷闷不乐到悲痛欲绝，自卑抑郁，甚至悲观厌世，可有自杀企图或行为；甚至发生木僵；部分病例有明显的焦虑和运动性激越；严重者可出现幻觉、妄想等精神病性症状。每次发作持续至少2周以上、长者甚或数年，多数病例有反复发作的倾向，每次发作大多数可以缓解，部分可有残留症状或转为慢性。 近日，丹麦第二大制药商灵北（Lundbeck）制药宣布，FDA批准治疗成人重型抑郁症后，抗抑郁新药Brintellix（vortioxetine）上市许可申请（MAA）获得了欧洲药品管理局（EMA）人用医药产品委员会（CHMP）的积极意见。CHMP建议批准Brintellix用于重型抑郁症（MDD）成人患者的治疗。Brintellix的起始剂量为：年龄小于65岁的成人患者为10mg/天。根据患者的个体反应，剂量可增加至最多20mg/天，或降低至最少5mg/天。 欧盟委员会（EC）通常会在2-3个月内做出最终审查决定，EC的审查决定适用于欧盟所有28个成员国及冰岛、列支敦士登、挪威。若获的最终批准，灵北计划于2014年上半年将Brintellix推向市场。 灵北已在一个全面的全球临床开发项目中对Brintellix进行了研究，整个项目涉及超过7000例患者。在重型抑郁症患者中开展的12个短期（6-8周）安慰剂对照研究中，有近4000例患者接受了Brintellix治疗。在9个研究中，与安慰剂相比，Brintellix表现出了统计学意义的显著、临床相关疗效，其中一个研究专门在中老年人中开展。 此外，一项为期12周的头对头（head-to-head）研究，也证明了Brintellix治疗重型抑郁症的疗效。该项研究，将最近获欧盟批准的抗抑郁症新药阿戈美拉汀（agomelatine）与Brintellix进行了对比。研究结果表明，Brintellix疗效显著优于agomelatine。 全球领先的制药与医疗保健问题研究和咨询公司——决策资源公司（DecisionResources）8月初发布报告预测，到2022年，抗抑郁新药Brintellix在美国、法国、德国、意大利、西班牙、英国、日本市场中将成为重磅药物。根据迄今取得的数据，鉴于其对认知的积极影响及可耐受的副作用属性，Brintellix预计将成为单相抑郁症市场中最成功的新药 --------------------------------------------- 产地国家:德国 原产地英文商品名: BRINTELLIX film coated tablet 5mg/Tablets  28Tablets 原产地英文药品名: VORTIOXETINE 中文参考商品译名: BRINTELLIX薄膜包衣片 5毫克/片 28片/盒 中文参考药品译名: 沃替西汀 生产厂家中文参考译名: 灵北/武田制药 生产厂家英文名: Lundbeck/Takeda --------------------------------------------- 产地国家:德国 原产地英文商品名: BRINTELLIX film coated tablet 10mg/Tablets  28Tablets 原产地英文药品名: VORTIOXETINE 中文参考商品译名: BRINTELLIX薄膜包衣片 10毫克/片 28片/盒 中文参考药品译名: 沃替西汀 生产厂家中文参考译名: 灵北/武田制药 生产厂家英文名: Lundbeck/Takeda --------------------------------------------- 产地国家:德国 原产地英文商品名: BRINTELLIX film coated tablet 20mg/Tablets  28Tablets 原产地英文药品名: VORTIOXETINE 中文参考商品译名: BRINTELLIX薄膜包衣片 20毫克/片 28片/盒 中文参考药品译名: 沃替西汀 生产厂家中文参考译名: 灵北/武田制药 生产厂家英文名: Lundbeck/Takeda --------------------------------------------- 产地国家:德国 原产地英文商品名: BRINTELLIX film coated tablet 5mg/Tablets  98Tablets 原产地英文药品名: VORTIOXETINE 中文参考商品译名: BRINTELLIX薄膜包衣片 5毫克/片 98片/盒 中文参考药品译名: 沃替西汀 生产厂家中文参考译名: 灵北/武田制药 生产厂家英文名: Lundbeck/Takeda --------------------------------------------- 产地国家:德国 原产地英文商品名: BRINTELLIX film coated tablet 10mg/Tablets  98Tablets 原产地英文药品名: VORTIOXETINE 中文参考商品译名: BRINTELLIX薄膜包衣片 10毫克/片 98片/盒 中文参考药品译名: 沃替西汀 生产厂家中文参考译名: 灵北/武田制药 生产厂家英文名: Lundbeck/Takeda --------------------------------------------- 产地国家:德国 原产地英文商品名: BRINTELLIX film coated tablet 20mg/Tablets  98Tablets 原产地英文药品名: VORTIOXETINE 中文参考商品译名: BRINTELLIX薄膜包衣片 20毫克/片 98片/盒 中文参考药品译名: 沃替西汀 生产厂家中文参考译名: 灵北/武田制药 生产厂家英文名: Lundbeck/Takeda